In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Berlin Heart's paediatric LVAD (left-ventricular assist device) in "record-breaking" UK recovery success:

This article was originally published in Clinica

Executive Summary

Berlin Heart has hit the UK headlines with the successful use of an external cardiac-assist device for what is claimed to be a record-breaking time. After the 8-month baby was given the go-ahead to remove life-support due to the severity of a myocarditis-induced heart attack, the Freeman Hospital, in Newcastle, still decided to use Berlin's EXCOR Pediatric left-ventricular assist device (LVAD) as a bridge to transplant, with an outside chance of success. After 120 days supported by the LVAD, followed by a fortnight's recovery, the now 13-month old has left hospital. The Berlin, Germany company is wholly-owned by long-term medtech investment company Syscore, since October 2006.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts